Blood Dna Articles & Analysis
8 news found
The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
The rapid, tumor-naïve plasma based test is designed to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage colorectal cancer (CRC) after curative intent surgery. xM was developed using the company’s multimodal database and advanced machine learning algorithms to accurately classify tumor fragments from non-tumor fragments, ...
ByTempus
While Radiomics will lead the radiological characterization of the cases included in the SALMON study through its proprietary advanced technology based on the extraction of quantitative information from DICOM scans, OncoDNA will generate comprehensive OncoKDM reports for the biological characterization and genetic sequencing of NSCLC patients via tissue and liquid biopsy, aimed at the analysis of ...
Latvian COVID-19 cohort includes various types of samples (blood, serum, plasma, oropharyngeal swabs, PBMC, feces, urine, isolated DNA, RNA), molecular data (blood biochemistry, cytokine panel, genome-wide genotyping, viral genome data, metagenome, metabolome, and transcriptome data) as well as excessive characterization of each clinical case. ...
At its virtual exhibition booth, IMB Dx will be presenting its liquid biopsy platform, the AlphaLiquid® product series, which detects and monitors minuscule amount of tumor DNA in the blood with high sensitivity. IMB Dx has already confirmed several meetings with various companies, including those from China, Vietnam, and Germany, that have expressed ...
Levels of microRNAs in the blood appear to be a reliable biomarker showing progression of Alzheimer’s. Yuval Dor, Ph.D. and colleagues at Hebrew University in Israel (up to $500,000 award) are refining a test they developed to detect levels of a brain-specific DNA in the blood. This DNA is only released into the ...
(NYSE: A) today introduced the new SureDirect Blood PCR Kit for amplification of DNA directly from blood and blood derivatives, without the need for nucleic acid extraction and isolation. ...